| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Oncology-Based In Vivo CRO Market Size 2024 |
USD 1114.5 Million |
| Oncology-Based In Vivo CRO Market, CAGR |
7% |
| Oncology-Based In Vivo CRO Market Size 2032 |
USD 1914.91 Million |
Market Overview:
The Oncology-Based In Vivo CRO Market is projected to grow from USD 1114.5 million in 2024 to USD 1914.91 million by 2032, at a CAGR of 7% from 2024 to 2032.
Several factors are driving the oncology-based in vivo CRO market. The increasing prevalence of cancer, which continues to be one of the leading causes of death worldwide, is a primary driver. Additionally, the growing focus on targeted therapies and immuno-oncology treatments requires specialized in vivo research models to evaluate the efficacy and safety of novel drug candidates. The increasing adoption of personalized medicine, which tailor’s treatment options based on individual patient profiles, further supports the demand for in vivo testing services. Moreover, collaborations between pharmaceutical companies, biotechnology firms, and CROs are enhancing research capabilities and accelerating oncology drug development processes. This growing collaboration is not only improving efficiency but also shortening time-to-market for novel therapies.
Geographically, North America holds the largest share of the oncology-based in vivo CRO market, owing to the presence of leading pharmaceutical companies, well-established research infrastructure, and high healthcare spending. The region’s robust regulatory environment and strong support for clinical research also contribute to its dominant position. Europe also represents a significant market due to the growing research activities and the increasing burden of cancer. The region benefits from a well-established healthcare framework and extensive investment in oncology research. The Asia-Pacific region is expected to experience the highest growth during the forecast period, driven by the expanding healthcare infrastructure, increasing cancer incidences, and growing outsourcing trends to CROs in countries such as China and India. This rapid growth in Asia-Pacific is supported by favorable government policies and increased foreign investments in the healthcare sector. These regions are expected to play a pivotal role in shaping the future of the market.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
Download Sample
Market Insights:
- The oncology-based in vivo CRO market is projected to grow significantly from USD 1114.5 million in 2024 to USD 1914.91 million by 2032.
- Targeted therapies and immuno-oncology treatments are key drivers of demand for specialized in vivo testing models.
- The adoption of personalized medicine is increasing the need for tailored in vivo models in oncology research.
- Collaborations between pharmaceutical companies, biotech firms, and CROs are accelerating cancer drug development.
- North America holds the largest market share, with strong research infrastructure and investment in oncology.
- The Asia-Pacific region is set for the highest growth due to increasing cancer incidences and expanding healthcare infrastructure.
- There is growing demand for reliable preclinical models as current in vivo models sometimes fail to predict human responses accurately.
Market Drivers:
Increasing Cancer Prevalence:
The rising incidence of cancer worldwide is a primary driver of the oncology-based in vivo contract research organization (CRO) market. For instance, the World Health Organization (WHO) reports significant investments in oncology research. As cancer remains one of the leading causes of death globally, the need for effective therapies is more pressing than ever. In vivo models provide critical insights into tumor biology, drug efficacy, and safety, driving demand for preclinical testing services. The growing cancer burden has significantly spurred investment in oncology research, thereby benefiting the CRO market.
Advancements in Targeted and Immuno-Oncology Therapies:
The shift toward personalized and targeted therapies is another significant market driver. In vivo models are essential for evaluating the efficacy and safety of these innovative therapies, such as immuno-oncology treatments. For instance, Bristol-Myers Squibb’s Opdivo (nivolumab) has demonstrated success in targeting specific molecules involved in cancer growth. These therapies, which focus on targeting specific molecules or cells involved in cancer growth, require precise and tailored preclinical testing. As the adoption of these treatments increases, so does the demand for specialized in vivo testing services, further boosting the CRO market.
Rising Adoption of Personalized Medicine:
The growing trend of personalized medicine, which tailor’s treatment options based on individual genetic profiles, is another driver of the oncology-based in vivo CRO market. For instance, Foundation Medicine offers comprehensive genomic profiling, enabling researchers to test drugs on patient-specific profiles, ensuring more accurate and effective treatment strategies. This move toward individualized care enhances the need for robust in vivo testing, pushing the demand for CRO services to new heights.
Collaborations and Outsourcing Trends:
Increasing collaborations between pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) are accelerating oncology drug development. For instance, Pfizer has partnered with ICON plc to enhance its oncology research efforts. Outsourcing research functions to CROs allows companies to streamline drug discovery and development, reduce costs, and gain access to specialized expertise. This trend is expected to continue driving the demand for oncology-based in vivo CRO services, supporting market growth.
Market Trends:
Growing Focus on Immuno-Oncology:
One of the key trends in the oncology-based in vivo CRO market is the growing focus on immuno-oncology (IO) therapies. These therapies, which utilize the body’s immune system to fight cancer, have shown significant promise in treating various cancer types. For instance, Merck’s Keytruda (pembrolizumab) has demonstrated success in treating melanoma and non-small cell lung cancer. As IO therapies become more prevalent, there is an increasing demand for in vivo models to evaluate their effectiveness and safety. CROs are adapting by enhancing their research capabilities to support the rapid development of immunotherapies, which is propelling market growth.
Adoption of 3D Cell Culture Models:
The integration of 3D cell culture models in in vivo research is another emerging trend in the oncology CRO market. Traditional 2D cell cultures often fail to mimic the complexities of human cancer, while 3D models offer a more accurate representation of tumor biology. For instance, Organovo’s 3D bioprinting technology is being utilized to create more reliable data for drug testing. As a result, in vivo CROs are adopting these advanced models to provide more reliable data for drug testing. The adoption of 3D cell cultures is expected to significantly improve the preclinical phase of drug development and enhance the overall effectiveness of oncology treatments.
Increase in Collaborative Partnerships:
Collaborative partnerships between CROs, pharmaceutical companies, and academic institutions are gaining traction in the oncology market. These collaborations enable more efficient drug development by pooling resources, knowledge, and technology. For example, AstraZeneca has established the Partners of Choice Network, comprising nine international cancer centers, to foster collaboration and enhance translational research. CROs are becoming integral to these partnerships, offering specialized expertise in in vivo testing and accelerating the delivery of new therapies. Such collaborations are expected to continue to play a pivotal role in the market, fostering innovation and speeding up clinical trials.
Shift Toward Precision Medicine:
Precision medicine is another notable trend driving the oncology-based in vivo CRO market. This approach tailors’ treatments to individual patients based on genetic, environmental, and lifestyle factors. For instance, Foundation Medicine offers comprehensive genomic profiling, enabling researchers to test drugs on patient-specific profiles, ensuring more accurate and effective treatment strategies. In vivo CROs are increasingly focusing on providing tailored preclinical models that align with the principles of precision medicine, ensuring that new cancer therapies are more effective and personalized. This shift is further propelling demand for specialized in vivo testing services.
Market Challenges Analysis:
High Cost of In Vivo Testing:
A significant challenge in the oncology-based in vivo CRO market is the high cost of in vivo testing. The need for specialized facilities, animal care, and advanced equipment, combined with the long duration of studies, increases the financial burden. This high cost can be a barrier, particularly for smaller biotechnology firms and startups, limiting their ability to access in vivo CRO services and slowing down innovation.
Ethical Concerns and Regulatory Compliance:
Ethical concerns surrounding animal testing continue to be a major challenge. The increasing scrutiny from regulatory bodies, animal welfare organizations, and the public regarding the use of animals in research creates pressure on CROs to adhere to stringent ethical guidelines. Additionally, the complex and varying regulatory requirements across regions complicate compliance, further delaying research and increasing operational costs. As ethical concerns evolve, CROs must balance research needs with responsible practices.
Variability in Preclinical Models:
The variability inherent in preclinical models is another key challenge. Although in vivo models are crucial for understanding drug efficacy and safety, they do not always accurately predict human responses due to biological differences between species. This can lead to misleading results, posing risks in drug development and clinical trial success. The need for more reliable and predictive models is becoming critical to ensure the effectiveness of in vivo testing.
Competition and Market Fragmentation:
The oncology-based in vivo CRO market is highly fragmented, with numerous players offering similar services. This intense competition makes it difficult for companies to differentiate themselves and establish long-term client relationships. As the demand for specialized in vivo testing grows, CROs must continually innovate, enhance service offerings, and build strong reputations to stay competitive in a crowded market.
Market Opportunities:
One of the significant market opportunities in the oncology-based in vivo CRO sector is the expansion into emerging markets. Regions like Asia-Pacific and Latin America offer substantial growth potential due to improving healthcare infrastructures, rising cancer incidences, and increasing investment in oncology research. Countries such as China, India, and Brazil are experiencing rapid healthcare advancements and growing demand for specialized oncology testing services. As pharmaceutical and biotechnology companies increasingly outsource research and development (R&D) activities, the demand for in vivo CRO services in these regions is expected to surge. Expanding into these markets presents a unique opportunity for CROs to tap into a growing client base and enhance their global presence.
Another key opportunity lies in the increasing integration of technological advancements in the oncology-based in vivo CRO market. The rise of personalized medicine has created a demand for more tailored and precise in vivo testing models. CROs can capitalize on this by developing specialized testing platforms that align with the growing focus on targeted therapies and immuno-oncology treatments. The ability to offer more accurate and predictive models will position CROs as leaders in this space, ensuring their services are critical in the drug development pipeline. Additionally, the use of 3D cell culture models and AI-driven data analysis presents new opportunities for enhancing the efficiency and reliability of preclinical oncology studies, further propelling market growth.
Market Segmentation Analysis:
By Indication:
The oncology-based in vivo CRO market is primarily segmented by indication, with different cancer types driving demand for specialized research services. Breast cancer is the largest segment, owing to its high global incidence and significant investment in the development of new therapies. In vivo models are crucial for evaluating the efficacy and safety of targeted therapies, chemotherapy, and immunotherapies in breast cancer. Lung cancer, which is the leading cause of cancer-related deaths worldwide, also plays a pivotal role in the market. The focus on immuno-oncology and targeted therapies in lung cancer research is generating substantial demand for in vivo testing services. Other significant segments include colorectal cancer, prostate cancer, and leukemia, each of which requires specialized in vivo models for testing a range of therapeutic options. In addition, emerging indications such as pancreatic cancer and ovarian cancer, which have lower survival rates and fewer effective treatment options, are gaining attention in oncology research. As the need for personalized medicine and more tailored therapies grows, so does the demand for specialized in vivo testing models to address the unique requirements of these cancer types. Consequently, the oncology-based in vivo CRO market continues to expand, driven by advancements in cancer research and the increasing number of indications requiring in vivo testing.
Segmentations:
By Indication:
-
- Syngeneic Model
- Patient Derived Xenograft (PDX)
- Blood Cancer
- Syngeneic Model
- Patient Derived Xenograft (PDX)
- Xenograft
- Other Indications
-
- Syngeneic Model
- Patient Derived Xenograft (PDX)
- Xenograft
By Region:
- North America
- Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis:
North America
North America dominates the oncology-based in vivo CRO market, accounting for 45% of the market share. The region benefits from a well-established healthcare infrastructure, a high prevalence of cancer, and substantial investments in oncology research. The presence of leading pharmaceutical and biotechnology companies, coupled with high healthcare spending, drives the demand for in vivo testing services. Additionally, the U.S. is home to some of the largest CROs, contributing to the region’s market leadership. The growing focus on personalized medicine and immuno-oncology further strengthens the demand for specialized in vivo models in North America. Regulatory support and a favorable research environment also play a significant role in the market’s expansion in this region.
Europe
Europe holds a 30% share of the oncology-based in vivo CRO market. The region’s growing cancer burden and increasing research activities in oncology contribute to this significant market share. European countries, particularly the U.K., Germany, and France, have made substantial investments in cancer research, driving demand for in vivo testing services. The emphasis on targeted therapies and precision medicine has led to a higher requirement for tailored in vivo models. Additionally, the region’s regulatory frameworks support drug development and preclinical testing, further fostering the market’s growth. Collaborations between pharmaceutical companies and CROs in Europe continue to enhance the region’s competitiveness in the oncology research space.
Asia-Pacific
The Asia-Pacific region holds 20% of the oncology-based in vivo CRO market share and is poised for the highest growth in the coming years. The increase in cancer incidence, combined with rising healthcare investments and an expanding pharmaceutical industry, fuels the demand for in vivo testing services. Countries like China, India, and Japan are driving this growth, with rapid advancements in healthcare infrastructure and increasing outsourcing trends in drug development. Additionally, regulatory improvements and government initiatives to support cancer research are contributing to the rise of in vivo CRO services in the region.
Rest of the World
The Rest of the World (RoW) region, which includes regions like Latin America, the Middle East, and Africa, holds a 5% share of the oncology-based in vivo CRO market. Though relatively small, the market in these regions is expanding as healthcare systems improve and cancer research initiatives increase. Growing demand for outsourced R&D services in these regions is expected to create new opportunities for CROs, leading to gradual market growth in the coming years.
Key Player Analysis:
- Charles River Laboratories
- Covance (Labcorp Drug Development)
- Envigo
- Pharmaron
- WuXi AppTec
- Celerion
- Kezar Life Sciences
- Taconic Biosciences
- Syngene International
- CROMSOURCE
Competitive Analysis:
The oncology-based in vivo CRO market is highly competitive, with key players vying for market share through innovative service offerings and strategic collaborations. Charles River Laboratories and Covance (Labcorp Drug Development) lead the market, leveraging their extensive portfolios and global presence to cater to diverse oncology research needs. These companies offer comprehensive in vivo testing services, including preclinical models, tumor efficacy testing, and immuno-oncology solutions. Smaller players, such as Pharmaron and Envigo, focus on niche markets, providing specialized in vivo models and expertise in early-stage drug development. They often differentiate themselves through tailored services and flexible solutions. The market is also witnessing increasing partnerships between CROs and pharmaceutical companies, enhancing their research capabilities and accelerating drug development processes. For example, Covance (Labcorp Drug Development) has partnered with Bristol-Myers Squibb to enhance their oncology research efforts. As oncology research progresses towards personalized treatments, players are investing heavily in advanced technologies like AI-driven models and 3D cell cultures to maintain a competitive edge and meet the evolving needs of the market.
Recent Developments:
- In April 2024, Charles River Laboratories announced the expansion of its oncology services with the launch of a new Oncology Discovery Services platform, focusing on advanced in vivo models to accelerate drug discovery and development.
- In March 2024, Envigo launched Envigo Oncology Solutions, a comprehensive suite of services aimed at supporting the entire drug development process from discovery to clinical trials, emphasizing the use of advanced in vivo models.
- In November 2023, Pharmaron expanded its Oncology Research Services by integrating new technologies like CRISPR/Cas9 for gene editing in preclinical models, enhancing the precision of oncology drug development.
Market Concentration & Characteristics:
The oncology-based in vivo CRO market is moderately concentrated, with a few large players dominating the space while smaller, specialized firms cater to niche segments. Major companies like Charles River Laboratories, Covance, and WuXi AppTec hold significant market share due to their established global presence, comprehensive service offerings, and robust research capabilities. These leaders provide a wide range of in vivo testing services, including preclinical models, tumor efficacy assessments, and personalized oncology solutions. Smaller players, such as Pharmaron and Envigo, focus on providing tailored services with high flexibility, often specializing in specific cancer indications or early-stage drug development. The market is characterized by strong competition, innovation in testing technologies, and strategic collaborations between CROs and pharmaceutical companies to accelerate cancer drug development. Additionally, the growing demand for personalized medicine and cutting-edge research models is driving the market toward more specialized and efficient solutions.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Report Coverage:
The research report offers an in-depth analysis based on Indication and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
- The demand for oncology-based in vivo CRO services will continue to grow due to the increasing prevalence of cancer worldwide.
- Advances in immuno-oncology and targeted therapies will drive further need for specialized in vivo testing models.
- Personalized medicine will play a key role in shaping the future of in vivo testing, requiring more tailored and precise models.
- Collaboration between pharmaceutical companies, biotech firms, and CROs will increase, fostering innovation in cancer drug development.
- Technological advancements such as 3D cell culture models and AI-driven analytics will enhance the accuracy and efficiency of in vivo testing.
- The rise of emerging markets, particularly in Asia-Pacific, will create significant growth opportunities for CROs.
- Regulatory frameworks will continue to evolve, requiring CROs to adapt to new compliance standards in different regions.
- As cancer research accelerates, demand for preclinical testing services in rare and hard-to-treat cancers will rise.
- Outsourcing trends in the pharmaceutical and biotechnology industries will further fuel the need for external in vivo research support.
- CROs will focus on expanding their capabilities by developing more sophisticated and predictive in vivo models to meet the evolving needs of cancer therapy development.
